ECSP22083926A - Compuestos útiles para inhibir la quinasa ret - Google Patents
Compuestos útiles para inhibir la quinasa retInfo
- Publication number
- ECSP22083926A ECSP22083926A ECSENADI202283926A ECDI202283926A ECSP22083926A EC SP22083926 A ECSP22083926 A EC SP22083926A EC SENADI202283926 A ECSENADI202283926 A EC SENADI202283926A EC DI202283926 A ECDI202283926 A EC DI202283926A EC SP22083926 A ECSP22083926 A EC SP22083926A
- Authority
- EC
- Ecuador
- Prior art keywords
- ret kinase
- compounds useful
- inhibiting ret
- ret
- inhibiting
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente se proporcionan inhibidores de la quinasa RET de acuerdo con la fórmula (I): sales aceptables desde el punto de vista farmacéutico de estos, composiciones farmacéuticas de estos y métodos para su uso en el tratamiento de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidas enfermedades y trastornos asociados a RET. A, R1, n, X1, X2, X3, X4, y R2 tienen los significados dados en la memoria descriptiva.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015933P | 2020-04-27 | 2020-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22083926A true ECSP22083926A (es) | 2022-11-30 |
Family
ID=75914595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202283926A ECSP22083926A (es) | 2020-04-27 | 2022-10-27 | Compuestos útiles para inhibir la quinasa ret |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11613533B2 (es) |
| EP (1) | EP4143184B1 (es) |
| JP (1) | JP7441972B2 (es) |
| KR (1) | KR102876271B1 (es) |
| CN (1) | CN115667253B (es) |
| AR (1) | AR121914A1 (es) |
| AU (1) | AU2021263541B2 (es) |
| BR (1) | BR112022021735A2 (es) |
| CA (1) | CA3177080A1 (es) |
| CL (1) | CL2022003000A1 (es) |
| CO (1) | CO2022016013A2 (es) |
| DO (1) | DOP2022000234A (es) |
| EC (1) | ECSP22083926A (es) |
| ES (1) | ES3029367T3 (es) |
| IL (1) | IL297551B2 (es) |
| JO (1) | JOP20220282A1 (es) |
| MX (1) | MX2022013482A (es) |
| PE (1) | PE20230780A1 (es) |
| TW (1) | TWI777509B (es) |
| WO (1) | WO2021222017A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3032873T3 (en) * | 2020-11-06 | 2025-07-28 | Lilly Co Eli | Pyrazole derivatives as ret kinase inhibitors |
| CN116421730B (zh) * | 2023-03-06 | 2025-08-01 | 浙江大学 | Cux1抑制剂及其用途 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| EP4574819A1 (en) | 2023-12-22 | 2025-06-25 | Basf Se | Diazinone compounds for the control of invertebrate pests |
| WO2025131957A1 (en) | 2023-12-22 | 2025-06-26 | Basf Se | Diazinone compounds for the control of invertebrate pests |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110189167A1 (en) * | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
| AU2014229233B2 (en) * | 2013-03-15 | 2016-08-11 | Glaxosmithkline Intellectual Property Development Limited | Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors |
| WO2017145050A1 (en) * | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
| WO2017161269A1 (en) * | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| JP6888101B2 (ja) * | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| CN112566907A (zh) * | 2018-08-17 | 2021-03-26 | 南京明德新药研发有限公司 | 作为ret抑制剂的吡唑衍生物 |
-
2021
- 2021-04-22 TW TW110114546A patent/TWI777509B/zh not_active IP Right Cessation
- 2021-04-22 AR ARP210101083A patent/AR121914A1/es not_active Application Discontinuation
- 2021-04-23 WO PCT/US2021/028836 patent/WO2021222017A1/en not_active Ceased
- 2021-04-23 IL IL297551A patent/IL297551B2/en unknown
- 2021-04-23 BR BR112022021735A patent/BR112022021735A2/pt unknown
- 2021-04-23 JP JP2022565547A patent/JP7441972B2/ja active Active
- 2021-04-23 PE PE2022002489A patent/PE20230780A1/es unknown
- 2021-04-23 US US17/238,370 patent/US11613533B2/en active Active
- 2021-04-23 ES ES21725633T patent/ES3029367T3/es active Active
- 2021-04-23 CN CN202180044981.8A patent/CN115667253B/zh active Active
- 2021-04-23 CA CA3177080A patent/CA3177080A1/en active Pending
- 2021-04-23 EP EP21725633.8A patent/EP4143184B1/en active Active
- 2021-04-23 MX MX2022013482A patent/MX2022013482A/es unknown
- 2021-04-23 AU AU2021263541A patent/AU2021263541B2/en active Active
- 2021-04-23 KR KR1020227041444A patent/KR102876271B1/ko active Active
-
2022
- 2022-10-27 EC ECSENADI202283926A patent/ECSP22083926A/es unknown
- 2022-10-27 DO DO2022000234A patent/DOP2022000234A/es unknown
- 2022-10-27 JO JOJO/P/2022/0282A patent/JOP20220282A1/ar unknown
- 2022-10-27 CL CL2022003000A patent/CL2022003000A1/es unknown
- 2022-11-09 CO CONC2022/0016013A patent/CO2022016013A2/es unknown
-
2023
- 2023-02-06 US US18/165,037 patent/US11964968B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20220282A1 (ar) | 2022-10-27 |
| DOP2022000234A (es) | 2022-11-30 |
| ES3029367T3 (en) | 2025-06-24 |
| KR102876271B1 (ko) | 2025-10-28 |
| CN115667253B (zh) | 2025-06-17 |
| PE20230780A1 (es) | 2023-05-09 |
| US20210363140A1 (en) | 2021-11-25 |
| CL2022003000A1 (es) | 2023-06-23 |
| AU2021263541B2 (en) | 2024-03-07 |
| CA3177080A1 (en) | 2021-11-04 |
| US20230312544A1 (en) | 2023-10-05 |
| AU2021263541A1 (en) | 2022-11-24 |
| TW202206428A (zh) | 2022-02-16 |
| EP4143184B1 (en) | 2025-04-23 |
| CO2022016013A2 (es) | 2022-11-18 |
| IL297551B1 (en) | 2024-02-01 |
| MX2022013482A (es) | 2022-11-16 |
| WO2021222017A1 (en) | 2021-11-04 |
| CN115667253A (zh) | 2023-01-31 |
| US11964968B2 (en) | 2024-04-23 |
| JP7441972B2 (ja) | 2024-03-01 |
| IL297551A (en) | 2022-12-01 |
| TWI777509B (zh) | 2022-09-11 |
| KR20230005301A (ko) | 2023-01-09 |
| BR112022021735A2 (pt) | 2022-12-06 |
| EP4143184A1 (en) | 2023-03-08 |
| IL297551B2 (en) | 2024-06-01 |
| JP2023523315A (ja) | 2023-06-02 |
| US11613533B2 (en) | 2023-03-28 |
| AR121914A1 (es) | 2022-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22083926A (es) | Compuestos útiles para inhibir la quinasa ret | |
| CO2023008167A2 (es) | Inhibidores de prmt5 | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| AR130689A1 (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| MX2020011250A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| CO2024000565A2 (es) | Inhibidores del inflamasoma nlrp3 | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| UY31679A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| UY30298A1 (es) | Inhibidores de la quinasa c-fms ii | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| ECSP23070418A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| UY40587A (es) | Inhibidores del inflamasoma nlrp3 | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CO2021003391A2 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR085308A1 (es) | Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| CL2022003812A1 (es) | Inhibidores de rip1k | |
| CL2025002808A1 (es) | Compuestos derivados de acilsulfonamida inhibidores de kat6a y uso para tratar cáncer. | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| PY2000386A (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| CR20240362A (es) | Compuestos heterocíclicos y métodos de uso | |
| AR131414A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso |